Optimizing Patient Care in Follicular and Marginal Zone Lymphomas Through Pharmacist Interventions

Program Description
Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are subtypes of B-cell non-Hodgkin lymphomas. Treatment of both malignancies is similar, with therapy options including observation, systemic cytotoxic chemotherapy, anti-CD20–targeted therapy, and oral therapies. Patient- and disease-specific factors guide therapy decisions, and pharmacists can play an integral role in assisting with treatment selection. This activity will review clinical data and guideline recommendations for the management of both FL and MZL, with an emphasis on oral oncolytics. Additionally, the role of the pharmacist in patient care will be discussed, showcasing how pharmacists can assist in patient education, monitoring, and follow-up.

Target audience: Health-system pharmacists

Type of activity: Application
Release date: December 20, 2021
Expiration date: June 20, 2022

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain how patient- or disease-specific factors may influence treatment decisions for a patient with follicular lymphoma (FL) or marginal zone lymphoma (MZL)
• Identify nuances among oral oncolytics used in the treatment of FL and MZL
• Apply knowledge of new and emerging oral oncolytics in therapy selection for FL and MZL
• Employ a team-based, longitudinal approach for monitoring and managing patients with FL or MZL

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-21-450-H01-P. The activity is available for CE credit through June 20, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Karen Fancher, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: AstraZeneca Pharmaceuticals, Merck & Co, BTG Specialty Pharmaceuticals

Speakers Bureau: G1 Therapeutics

Bernard Marini, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Meg Taylor PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms